Metoprolol succinate drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Succinate Drug Interactions
Introduction to Metoprolol Succinate
Metoprolol succinate is a cardioselective beta-1 adrenergic receptor blocker commonly used to manage hypertension, angina, and heart failure. Its extended-release formulation ensures a consistent therapeutic effect over a 24-hour period, enhancing patient compliance and therapeutic outcomes .
Interaction with Telmisartan
A study on the combination of metoprolol succinate and telmisartan, an angiotensin receptor blocker, revealed no significant pharmacokinetic interactions when co-administered. The combination therapy showed an improved antihypertensive effect without additive toxic effects, suggesting a safe profile for concurrent use .
Interaction with Paroxetine
Paroxetine, a CYP2D6 inhibitor, significantly affects the pharmacokinetics of metoprolol succinate. Co-administration with paroxetine increases the plasma concentration of metoprolol by 3-4 times, potentially leading to enhanced beta-blockade and reduced cardioselectivity. This interaction is similar for both immediate-release and extended-release formulations of metoprolol .
Interaction with Palmitic Acid
Palmitic acid can displace metoprolol succinate from its binding sites on bovine serum albumin, increasing the free fraction of the drug in the plasma. This displacement effect is further amplified in the presence of other drugs like ranitidine and diazepam, which can significantly alter the pharmacokinetic properties of metoprolol succinate .
Combination with Atorvastatin
A bilayered tablet combining metoprolol succinate (sustained release) and atorvastatin calcium (immediate release) has been developed to manage hypertension and hyperlipidemia simultaneously. This combination aims to reduce dosing frequency and improve patient compliance. The optimized formulation controls drug release effectively over a 24-hour period .
Conclusion
Metoprolol succinate interacts with various drugs, influencing its pharmacokinetic and pharmacodynamic properties. While combinations with telmisartan and atorvastatin show promise for enhanced therapeutic effects and patient compliance, interactions with paroxetine and palmitic acid require careful monitoring due to significant alterations in drug plasma levels. Understanding these interactions is crucial for optimizing treatment regimens and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic